The Importance of Vascular Density in Progression of Prostate Cancer Undergoing Radical Prostatectomy
Keywords:
prostate cancer, tumor progression, vascular density, vascular vessel, lymphatic vessels, hormone-native patients
Abstract
Development of vascularization in tumor by supporting the nutrition and dissemination of tumor cells. However, the reduced number of vascular density (VVlow) may bring to hypoxia, which accounts for the selection of resistant clone(s) of tumor cells. This research focused on to evaluate the prognostic importance of blood vessel (VV) and lymphatic vessel (LV) in disease progression in prostate cancer (PCa). Tumor samples from 85 prostate cancer patients undergoing radical prostatectomy (RP) were prepared in duplex as tissue microarrays. All VV and LV were estimated using immunohistochemistry detecting CD34 and podoplanin, respectively, and correlated with clinical data, biochemical recurrence (BR), and proteins analyzed in tumor cells.
VVlow and LV were found in 13% and 24% of patients with informative prostate cancer samples, respectively. VVlow correlated with a shorter time to BR 1, 3, and 5 years after RP in hormone-native patients (p = 0.021, p = 0.024 and p = 0.040, respectively). Also these are shown to be an independent prognostic factor 3 years after surgery (multivariate analysis, p = 0.041). Tumors characterized by VVlow expressed the epithelial cell adhesion molecule, EpCAM, less frequently (p = 0.014) and revealed a borderline correlation to increased levels of tumor cell invasion marker Loxl-2 (p = 0.043). No correlations were found for LV. In summary, VVlow in hormone-native patients undergoing RP has prognostic potential and seems to be related to an aggressive phenotype of tumor cells.
References
1. Aripova O.E., Chernogubova E.A. “Analysis of prostate cancer in the Rostov region for 2001-2016”. Journal Bulletin of Urology Volume No. 12, No.4 2016. [Аrxipova O.E., ChernogubovaYe.ААnaliz zabolevanie rakom predstatelnoy jelezi n aRostovskoy oblasti 2001-2016gg. prostranstvo –vremennaya stastistika. Jurnal Vestnik Urologii Tom №12, №4 2016]
2. Asratov A.T., Kalpinsky A.S., Taraki I.A., SamsonovYu.V., Kostin A.A. “PROSTATE CANCER WITH A HIGH BASELINE LEVEL OF PROSTATE-SPECIFIC ANTIGEN AFTER COMBINED TREATMENT.” Research and practice in medicine. 2017;4(4):133-142. [Asratov A.T., Kalpinskij A.S., Taraki I.A., Samsonov YU.V., Kostin A.A. RAK PREDSTATEL'NOJ ZHELEZY S VYSOKIM ISKHODNYM UROVNEM PROSTATSPECIFICHESKOGO ANTIGENA POSLE KOMBINIROVANNOGO LECHENIYA. Issledovaniya i praktika v medicine. 2017;4(4):133-142.]
3. Bezrukov E.A., Lachinov E.L., Martirosyan G.A., et al. “Factors of local recurrence after radical prostatectomy.” Medical Bulletin of Bashkortostan Volume 10, No. 3 2015 pp. 12-13. [Bezrukov E.A., Lachikov E.L., Martirosyan G.A., idr. Faktorymestnogorecedivaposleradikal'nojprostatektomii. MedicinskijVestnikBashkortastana Tom10, №3 2015 str. 12-1]
4. Glybochko P.V., AlyaevYu.G., Krupinov G.E. and co. “Diagnosis and treatment of local recurrence of prostate cancer using histoscanning and high-intensity focused ultrasound in patients after radical prostatectomy.” Urology Journal No. 5 2014.[Glybochko P.V., Alyaev YU.G, Krupinov G.E. isoav. Diagnostikailechenielokal'nogorecidivarakapredstatel'nojzhelezy s Nat. Volatiles & Essent. Oils, 2021; 8(4): 15980-15989 15987 ispol'zovaniemgistoskanirovaniyaivysokointensivnogofokusirovannogoul'trazvuka u pacientovposleradikal'nojprostatektomii. ZurnalUrologiya №5 2014]
5. Dengina N.V., Panchenko S.V., Rodionov V.V. “RADIATION THERAPY AFTER RADICAL PROSTATECTOMY: WHEN AND FOR WHOM? Malignanttumors. 2013;(1):41-46. [Den'gina N.V., Panchenko S.V., Rodionov V.V. LUCHEVAYA TERAPIYA POSLE RADIKAL'NOJ PROSTATEKTOMII: KOGDA I DLYA KOGO? Zlokachestvennye opuholi. 2013;(1):41-46.]
6. Enikeev O.V., Rapoport L.M., Amosov A.V., et al. “Postoperative complications of minimally invasive methods of prostate cancer treatment.” Oncourology No.3, No.4 2018 p.46. [Enikeev O.V., Rapoport L.M., Amosov A.V., idr. Posleoperacionnayaoslozhneniyamaloinvazivnyhmetodovlecheniyarakapredstatel'nojzhelezy. Onkourologiya №3,№4 2018g str.46]
7. Kaprin A.D., Biryukov V.A., Chernichenko A.V., etc. “Brachytherapy for prostate cancer. Work experience of branches of the National Medical Research Center of Radiology.” Oncourology 2018;14(1):94-9. [Kaprin A.D., Biryukov V.A., CHernichenko A.V. idr. Brahiterapiyarakapredstatel'nojzhelezy. OpytrabotyfilialovNacional'nogomedicinskogoissledovatel'skogocentraradiologii. Onkourologiya 2018;14(1):94–9.]
8. Kaprin A.D., Biryukov V.A., Chernichenko A.V., etc. “Brachytherapy for prostate cancer. Work experience of branches of the National Medical Research Center of Radiology.” Oncourology 2018;14(1):94-9.[Karyakin O.B. PRIORITETY V LECHENII RAZLICHNYH STADIJ RAKA PREDSTATEL'NOJ ZHELEZY II ROSSIJSKAYA ONKOLOGICHESKAYA KONFERENCIYA Moskva 2019]
9. Lapteva T.O. “Path morphological evaluation of the prostate after radical prostatectomy.” Bulletin of Urology. 2019;7(1):74-83.[Lapteva T.O. Patomorfologicheskayaocenkaprostatyposleradikal'nojprostatektomii. Vestnikurologii. 2019;7(1):74-83.]
10. Laurent O.B., Veliev E.I., Kotov S.V. ONCOLOGICAL RESULTS OF RADICAL SURGICAL TREATMENT IN PATIENTS WITH LOCALLY ADVANCED PROSTATE CANCER. Oncourology. 2009;5(3):29-34. [Loran O.B., Veliev E.I., Kotov S.V. ONKOLOGICHESKIE REZUL'TATY RADIKAL'NOGO HIRURGICHESKOGO LECHENIYA U PACIENTOV S MESTNO-RASPROSTRANENNYM RAKOM PREDSTATEL'NOJ ZHELEZY. Onkourologiya. 2009;5(3):29-34.]
11. Novikov N.D. "Treatment with high-intensity focused ultrasound of patients with local recurrence of prostate cancer after radical prostatectomy" Journal of Oncourology of Russia 2016 No. 2 P-14-15. [Novichkov N.D. «Lechenievysokointensivnymfokusirovannymul'trazvukombol'nyh s Nat. Volatiles & Essent. Oils, 2021; 8(4): 15980-15989 15988 mestnymrecidivomrakapredstatel'nojzhelezyposleradikal'nojprostatektomii» ZHurnalOnkourologiiRossii 2016 №2 S-14-15]
12. Pushkar D.Yu.,Evdokimova A.I., Rasner P.I., etc. “Prostate cancer. Regular issues of "RMJ" No. 17 2014 p. 5. [Pushkar' D.YU.,Evdokimova A.I., Rasner P.I. i dr. Rakpredstatel'nojzhelezy. Regulyarnyevypuski «RMZH» №17 2014 str. 5]
13. Rusakov I.G., Savkov R.V. “Neoadjuvant and adjuvant hormone therapy for prostate cancer.” Journal of Experimental and Clinical Urology. No.2 2019 pp.61-64. [Rusakov I.G., Savkov R.V. Neoad"yuvantnayaiad"yuvantnayagormonal'nayaterapiyarakapredstatel'nojzhelezy. ZHurnalEksperimental'nayaiKlinicheskayaUrologiya. №2 2019 str.61-64]
14. Tomkevich B.A. “Optimization of treatment of patients with locally advanced prostate cancer at stage” T3NxM0 2006 Moscow. [Tomkevich B.A. AvtoreferatOptimizaciyalecheniyabol'nyhmestnorasprostranennymrakompredstatel'nojzhelezy v stadii T3NxM0 2006g Moskva]
15. Tillyashaykhov M.N. “Modern approaches to treatment of advanced prostate cancer 2019.” [Tillyashaihov M.N. AvtoreferatSovremennyjpodhodylechenie v rasprostranennogorakapredstatel'nojzhelezy 2019]
16. Frank G.A. “Morphology of prostate cancer.” Practical Oncology T9 No. 2 2008 p. 68. [Frank G.A. Morfologiyarakapredstatel'nojzhelezy. PrakticheskayaOnkologiya T9 №2 2008g str. 68]
17. Khvastunov R.A. “Lecture dedicated to modern problems of diagnosis and treatment of prostate cancer.” Volgograd State Medical University, Quarterly Scientific and Practical Journal 3 (27) JulySeptember 2008. [Hvastunov R.A. Lekciya posvyashchenie sovremennym problemami diagnostikii lecheniya raka predstatel'no jzhelezy. VolgogradskogoGosudarstvennogoMedicinskogoUniversiteta, ezhkvartal'nyjnauchnoprakticheskijzhurnal 3 (27) iyulb-sentyabr' 2008]
18. Khmara T.G., Chekhonatskaya M.L., Priezzheva V.N., Ilyasova E.B., Kochakov S.V. “Correspondence conference "Actual problems of fundamental and clinical uronephrology" 2014 Urology. [Hmara T.G, CHekhonackaya M.L., Priezzheva V.N., Ilyasova E.B., Kochakov S.V. Zaochnayakonferenciya «Aktual'nyeproblemyfundamental'nojiklinicheskojuronefrologii» 2014 Urologiya]
19. Chernyshev I.V., SamsonovYu.V., Koryakin A.V. “Principles of hormone therapy for prostate cancer.” Research Institute of Urology of Rosmedtechnology "EFFECTIVE PHARMACOTHERAPY. Urology and Nephrology" No. 4. [CHernyshev I.V, Samsonov YU.V., Koryakin A.V. Principygormonal'nojterapiirakapredstatel'nojzhelezy. NII urologiiRosmedtekhnologij "EFFEKTIVNAYA FARMAKOTERAPIYA. UrologiyaiNefrologiya" №4] Nat. Volatiles & Essent. Oils, 2021; 8(4): 15980-15989 15989
20. American Cancer Society, Atlanta 2019 Cancer Journal for Clinicians The facts & Figures annual report.
21. Arenas L.F., Fullhanse C., Boemans P. UrologischeKlinikEvangelisches und JohanniterKlinikumNiederrhein, Oberhausen Germany Aktuelle Urol.2010 Jan.Supp.1 S 10-4 22.
22. EAU-ESTRO –SIDG Guidlenes on Prostate Cancer 2017
23. A V Bono, N Celato, V Cova, M Salvadore, S Chinetti & R Novario Microvessel density in prostate carcinoma Prostate Cancer and Prostatic Diseases volume 5, pages123–127 (2002)
24. EmmaHuebner and AlBarqawi. Archives of Surgical Oncology, 2015: 106 DOI: 10.4172/2471-2671.1000106
25. Chalouhy Ch., Ghavamian R., Urologic Oncology: Seminars and Original Investigations Vol.37 Issue 3 March 2019 pg.219-226
26. Guangui Feng , Kai Wang and Zhao Jiang Microvessel density as a prognostic indicator of prostate cancer: A systematic review and meta-analysis. From the journal Open Medicine https://doi.org/10.1515/med-2020-0235
27. I F Lissbrant 1, P Stattin, J E Damber, A Bergh Vascular density is a predictor of cancer-specific survival in prostatic carcinoma PMID: 929462: 10.1002/(sici)1097-0045(19970915)33:1<38::aid-pros7>3.0.co;2-5
28. Herbert Lepor, MD A Review of Surgical Techniques for Radical Prostatectomy Rev Urol. 2005; 7(Suppl 2): S11–S17.
29. Joanna B. Madalinska , Marie-Louise Essink-Bot , Harry J. de Koning , Wim J. Kirkels , Paul J. van der Maas , Fritz H. Schröder DOI: 10.1200/JCO.2001.19.6.1619 Journal of Clinical Oncology 19, no. 6 (March 15, 2001) 1619-1628. Published online September 21, 2016.
30. Monika Ulamec University Clinical Hospital Center "Sestre Milosrdnice"2. Davor Tomas Medical school, University of Zagreb 3.Hrvoje Cupic University Clinical Hospital Center "Sestre Milosrdnice 4.Bozo Kruslin Klinički bolnički centar Sestre milosrdnic Lymph Vessel Density in Prostatic Cancer and Adjacent Nontumorous Tissue https://www.researchgate.net/publication/27223640
31. Philippou YA, Jung JH, Steggall MJ, O'Driscoll ST, Bakker CJ, Bodie JA, Dahm P. Cochrane review on MRI featured in Urology Times: https://www.urologytimes.com/prostate-cancer/review-mri-pathway-mostaccurate-strategy-detecting-clinically-significant-pcancer
32. Ryan Mark J. MD Role of Genetic Testing for inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017
33. Sanda M.G., Dunn R.L., Michalski J.et all. “Quality of life and Satisfaction with outcome among prostate cancer survivors.”England Journal Medicine 2008; 358 (12); 1250-61 DOL: 10.1056\NEJM 074311
34. Tal R. [et al.] “Erectile function recovery rate after radical prostatectomy: a meta-analysis” // J Sex Med. – 2009. – Vol. 6, №9. – pp. 253-254
35. Yiping Zeng 1, Kenneth Opeskin, Lisa G Horvath, Robert L Sutherland, Elizabeth D Williams Lymphatic vessel density and lymph node metastasis in prostate cancer PMID: 159481: 10.1002/pros.20288
2. Asratov A.T., Kalpinsky A.S., Taraki I.A., SamsonovYu.V., Kostin A.A. “PROSTATE CANCER WITH A HIGH BASELINE LEVEL OF PROSTATE-SPECIFIC ANTIGEN AFTER COMBINED TREATMENT.” Research and practice in medicine. 2017;4(4):133-142. [Asratov A.T., Kalpinskij A.S., Taraki I.A., Samsonov YU.V., Kostin A.A. RAK PREDSTATEL'NOJ ZHELEZY S VYSOKIM ISKHODNYM UROVNEM PROSTATSPECIFICHESKOGO ANTIGENA POSLE KOMBINIROVANNOGO LECHENIYA. Issledovaniya i praktika v medicine. 2017;4(4):133-142.]
3. Bezrukov E.A., Lachinov E.L., Martirosyan G.A., et al. “Factors of local recurrence after radical prostatectomy.” Medical Bulletin of Bashkortostan Volume 10, No. 3 2015 pp. 12-13. [Bezrukov E.A., Lachikov E.L., Martirosyan G.A., idr. Faktorymestnogorecedivaposleradikal'nojprostatektomii. MedicinskijVestnikBashkortastana Tom10, №3 2015 str. 12-1]
4. Glybochko P.V., AlyaevYu.G., Krupinov G.E. and co. “Diagnosis and treatment of local recurrence of prostate cancer using histoscanning and high-intensity focused ultrasound in patients after radical prostatectomy.” Urology Journal No. 5 2014.[Glybochko P.V., Alyaev YU.G, Krupinov G.E. isoav. Diagnostikailechenielokal'nogorecidivarakapredstatel'nojzhelezy s Nat. Volatiles & Essent. Oils, 2021; 8(4): 15980-15989 15987 ispol'zovaniemgistoskanirovaniyaivysokointensivnogofokusirovannogoul'trazvuka u pacientovposleradikal'nojprostatektomii. ZurnalUrologiya №5 2014]
5. Dengina N.V., Panchenko S.V., Rodionov V.V. “RADIATION THERAPY AFTER RADICAL PROSTATECTOMY: WHEN AND FOR WHOM? Malignanttumors. 2013;(1):41-46. [Den'gina N.V., Panchenko S.V., Rodionov V.V. LUCHEVAYA TERAPIYA POSLE RADIKAL'NOJ PROSTATEKTOMII: KOGDA I DLYA KOGO? Zlokachestvennye opuholi. 2013;(1):41-46.]
6. Enikeev O.V., Rapoport L.M., Amosov A.V., et al. “Postoperative complications of minimally invasive methods of prostate cancer treatment.” Oncourology No.3, No.4 2018 p.46. [Enikeev O.V., Rapoport L.M., Amosov A.V., idr. Posleoperacionnayaoslozhneniyamaloinvazivnyhmetodovlecheniyarakapredstatel'nojzhelezy. Onkourologiya №3,№4 2018g str.46]
7. Kaprin A.D., Biryukov V.A., Chernichenko A.V., etc. “Brachytherapy for prostate cancer. Work experience of branches of the National Medical Research Center of Radiology.” Oncourology 2018;14(1):94-9. [Kaprin A.D., Biryukov V.A., CHernichenko A.V. idr. Brahiterapiyarakapredstatel'nojzhelezy. OpytrabotyfilialovNacional'nogomedicinskogoissledovatel'skogocentraradiologii. Onkourologiya 2018;14(1):94–9.]
8. Kaprin A.D., Biryukov V.A., Chernichenko A.V., etc. “Brachytherapy for prostate cancer. Work experience of branches of the National Medical Research Center of Radiology.” Oncourology 2018;14(1):94-9.[Karyakin O.B. PRIORITETY V LECHENII RAZLICHNYH STADIJ RAKA PREDSTATEL'NOJ ZHELEZY II ROSSIJSKAYA ONKOLOGICHESKAYA KONFERENCIYA Moskva 2019]
9. Lapteva T.O. “Path morphological evaluation of the prostate after radical prostatectomy.” Bulletin of Urology. 2019;7(1):74-83.[Lapteva T.O. Patomorfologicheskayaocenkaprostatyposleradikal'nojprostatektomii. Vestnikurologii. 2019;7(1):74-83.]
10. Laurent O.B., Veliev E.I., Kotov S.V. ONCOLOGICAL RESULTS OF RADICAL SURGICAL TREATMENT IN PATIENTS WITH LOCALLY ADVANCED PROSTATE CANCER. Oncourology. 2009;5(3):29-34. [Loran O.B., Veliev E.I., Kotov S.V. ONKOLOGICHESKIE REZUL'TATY RADIKAL'NOGO HIRURGICHESKOGO LECHENIYA U PACIENTOV S MESTNO-RASPROSTRANENNYM RAKOM PREDSTATEL'NOJ ZHELEZY. Onkourologiya. 2009;5(3):29-34.]
11. Novikov N.D. "Treatment with high-intensity focused ultrasound of patients with local recurrence of prostate cancer after radical prostatectomy" Journal of Oncourology of Russia 2016 No. 2 P-14-15. [Novichkov N.D. «Lechenievysokointensivnymfokusirovannymul'trazvukombol'nyh s Nat. Volatiles & Essent. Oils, 2021; 8(4): 15980-15989 15988 mestnymrecidivomrakapredstatel'nojzhelezyposleradikal'nojprostatektomii» ZHurnalOnkourologiiRossii 2016 №2 S-14-15]
12. Pushkar D.Yu.,Evdokimova A.I., Rasner P.I., etc. “Prostate cancer. Regular issues of "RMJ" No. 17 2014 p. 5. [Pushkar' D.YU.,Evdokimova A.I., Rasner P.I. i dr. Rakpredstatel'nojzhelezy. Regulyarnyevypuski «RMZH» №17 2014 str. 5]
13. Rusakov I.G., Savkov R.V. “Neoadjuvant and adjuvant hormone therapy for prostate cancer.” Journal of Experimental and Clinical Urology. No.2 2019 pp.61-64. [Rusakov I.G., Savkov R.V. Neoad"yuvantnayaiad"yuvantnayagormonal'nayaterapiyarakapredstatel'nojzhelezy. ZHurnalEksperimental'nayaiKlinicheskayaUrologiya. №2 2019 str.61-64]
14. Tomkevich B.A. “Optimization of treatment of patients with locally advanced prostate cancer at stage” T3NxM0 2006 Moscow. [Tomkevich B.A. AvtoreferatOptimizaciyalecheniyabol'nyhmestnorasprostranennymrakompredstatel'nojzhelezy v stadii T3NxM0 2006g Moskva]
15. Tillyashaykhov M.N. “Modern approaches to treatment of advanced prostate cancer 2019.” [Tillyashaihov M.N. AvtoreferatSovremennyjpodhodylechenie v rasprostranennogorakapredstatel'nojzhelezy 2019]
16. Frank G.A. “Morphology of prostate cancer.” Practical Oncology T9 No. 2 2008 p. 68. [Frank G.A. Morfologiyarakapredstatel'nojzhelezy. PrakticheskayaOnkologiya T9 №2 2008g str. 68]
17. Khvastunov R.A. “Lecture dedicated to modern problems of diagnosis and treatment of prostate cancer.” Volgograd State Medical University, Quarterly Scientific and Practical Journal 3 (27) JulySeptember 2008. [Hvastunov R.A. Lekciya posvyashchenie sovremennym problemami diagnostikii lecheniya raka predstatel'no jzhelezy. VolgogradskogoGosudarstvennogoMedicinskogoUniversiteta, ezhkvartal'nyjnauchnoprakticheskijzhurnal 3 (27) iyulb-sentyabr' 2008]
18. Khmara T.G., Chekhonatskaya M.L., Priezzheva V.N., Ilyasova E.B., Kochakov S.V. “Correspondence conference "Actual problems of fundamental and clinical uronephrology" 2014 Urology. [Hmara T.G, CHekhonackaya M.L., Priezzheva V.N., Ilyasova E.B., Kochakov S.V. Zaochnayakonferenciya «Aktual'nyeproblemyfundamental'nojiklinicheskojuronefrologii» 2014 Urologiya]
19. Chernyshev I.V., SamsonovYu.V., Koryakin A.V. “Principles of hormone therapy for prostate cancer.” Research Institute of Urology of Rosmedtechnology "EFFECTIVE PHARMACOTHERAPY. Urology and Nephrology" No. 4. [CHernyshev I.V, Samsonov YU.V., Koryakin A.V. Principygormonal'nojterapiirakapredstatel'nojzhelezy. NII urologiiRosmedtekhnologij "EFFEKTIVNAYA FARMAKOTERAPIYA. UrologiyaiNefrologiya" №4] Nat. Volatiles & Essent. Oils, 2021; 8(4): 15980-15989 15989
20. American Cancer Society, Atlanta 2019 Cancer Journal for Clinicians The facts & Figures annual report.
21. Arenas L.F., Fullhanse C., Boemans P. UrologischeKlinikEvangelisches und JohanniterKlinikumNiederrhein, Oberhausen Germany Aktuelle Urol.2010 Jan.Supp.1 S 10-4 22.
22. EAU-ESTRO –SIDG Guidlenes on Prostate Cancer 2017
23. A V Bono, N Celato, V Cova, M Salvadore, S Chinetti & R Novario Microvessel density in prostate carcinoma Prostate Cancer and Prostatic Diseases volume 5, pages123–127 (2002)
24. EmmaHuebner and AlBarqawi. Archives of Surgical Oncology, 2015: 106 DOI: 10.4172/2471-2671.1000106
25. Chalouhy Ch., Ghavamian R., Urologic Oncology: Seminars and Original Investigations Vol.37 Issue 3 March 2019 pg.219-226
26. Guangui Feng , Kai Wang and Zhao Jiang Microvessel density as a prognostic indicator of prostate cancer: A systematic review and meta-analysis. From the journal Open Medicine https://doi.org/10.1515/med-2020-0235
27. I F Lissbrant 1, P Stattin, J E Damber, A Bergh Vascular density is a predictor of cancer-specific survival in prostatic carcinoma PMID: 929462: 10.1002/(sici)1097-0045(19970915)33:1<38::aid-pros7>3.0.co;2-5
28. Herbert Lepor, MD A Review of Surgical Techniques for Radical Prostatectomy Rev Urol. 2005; 7(Suppl 2): S11–S17.
29. Joanna B. Madalinska , Marie-Louise Essink-Bot , Harry J. de Koning , Wim J. Kirkels , Paul J. van der Maas , Fritz H. Schröder DOI: 10.1200/JCO.2001.19.6.1619 Journal of Clinical Oncology 19, no. 6 (March 15, 2001) 1619-1628. Published online September 21, 2016.
30. Monika Ulamec University Clinical Hospital Center "Sestre Milosrdnice"2. Davor Tomas Medical school, University of Zagreb 3.Hrvoje Cupic University Clinical Hospital Center "Sestre Milosrdnice 4.Bozo Kruslin Klinički bolnički centar Sestre milosrdnic Lymph Vessel Density in Prostatic Cancer and Adjacent Nontumorous Tissue https://www.researchgate.net/publication/27223640
31. Philippou YA, Jung JH, Steggall MJ, O'Driscoll ST, Bakker CJ, Bodie JA, Dahm P. Cochrane review on MRI featured in Urology Times: https://www.urologytimes.com/prostate-cancer/review-mri-pathway-mostaccurate-strategy-detecting-clinically-significant-pcancer
32. Ryan Mark J. MD Role of Genetic Testing for inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017
33. Sanda M.G., Dunn R.L., Michalski J.et all. “Quality of life and Satisfaction with outcome among prostate cancer survivors.”England Journal Medicine 2008; 358 (12); 1250-61 DOL: 10.1056\NEJM 074311
34. Tal R. [et al.] “Erectile function recovery rate after radical prostatectomy: a meta-analysis” // J Sex Med. – 2009. – Vol. 6, №9. – pp. 253-254
35. Yiping Zeng 1, Kenneth Opeskin, Lisa G Horvath, Robert L Sutherland, Elizabeth D Williams Lymphatic vessel density and lymph node metastasis in prostate cancer PMID: 159481: 10.1002/pros.20288
Published
2022-12-07
How to Cite
Tillyashaykhov, M. N., & Salomov, M. S. (2022). The Importance of Vascular Density in Progression of Prostate Cancer Undergoing Radical Prostatectomy. Central Asian Journal of Medical and Natural Science, 3(6), 281-292. Retrieved from https://cajmns.centralasianstudies.org/index.php/CAJMNS/article/view/1205
Section
Articles
